Which Sinopharm-linked vaccine was approved earlier, and when?

Question

Accepted Answer

The Sinopharm-linked vaccine approved in December was the first to receive formal public use authorisation in China.

A vaccine developed by a Beijing institute affiliated with the state-owned China National Pharmaceutical Group (Sinopharm) received formal approval for general public use in December. This approval preceded the formal authorisation of the Sinovac Biotech vaccine, which was announced on February 6.
Sinopharm Vaccine's December Approval

The vaccine linked to Sinopharm was approved in December, making it the first of the two mentioned vaccines to be green-lighted for public use in China. This marked a significant step in the country's public health strategy against the Covid-19 pandemic.
Pre-Approval Vaccination Programmes

Both the Sinopharm-linked vaccine and the Sinovac vaccine had already been incorporated into China's vaccination programme prior to their formal public approvals. These programmes primarily focused on vaccinating individuals identified as being at a higher risk of exposure to the virus.
Basis for Approval

The approval for the Sinovac vaccine, as stated, was based on two-month results from overseas late-stage clinical trials, although final analysis data had not yet been obtained. Information regarding the specific basis for the Sinopharm vaccine's approval in December is not detailed in the provided text.

Reading history

Hide →

This history is cleared when the page is closed.

Which Sinopharm-linked vaccine was approved earlier, and when?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends